Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
The trial investigates the effectiveness and safety of two dosing schedules of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stages F2 or F3. This phase 3 study focuses on people aged 18 to 80 years and aims to better understand treatment options for this liver condition. Participants will be randomly assigned to receive one of two pegozafermin regimens or a matching placebo. Both pegozafermin and placebo are given by subcutaneous injection. The study includes a treatment period lasting up to 52 weeks, during which the effects of these regimens on liver fibrosis and steatohepatitis will be assessed. Throughout the study, participants will undergo various evaluations including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and monitoring for disease progression for up to five years. Researchers will track improvements in liver fibrosis, resolution of steatohepatitis, changes in liver enzyme levels, and fibrosis scores to assess the impact of the treatments.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of lebrikizumab, a drug given by injection, in people aged 12 and older with chronic rhinosinusitis and nasal polyps who are also treated with intranasal corticosteroids. This phase 3 trial aims to improve symptoms like nasal congestion and polyp size while monitoring participant safety over about 18 months. Participants receive lebrikizumab injections on different schedules or placebo injections, all along with standard intranasal corticosteroid spray. Adolescents aged 12 to under 18 who weigh at least 40 kg are assigned to open-label lebrikizumab treatment. The study includes multiple groups receiving injections every 2, 4, or 8 weeks to compare outcomes. During the study, participants will undergo assessments including nasal congestion scoring, endoscopic evaluation of nasal polyps, sinus imaging, lung function tests, and symptom questionnaires from the start through 24 weeks. Safety and symptom changes are closely monitored, and the total study duration is approximately 18 months.
Actively Recruiting
Researchers are conducting a master protocol consisting of three independent, multicenter, randomized, double-blind, placebo-controlled studies to evaluate ACP-204 in adults with Alzheimers Disease Psychosis ADP. The purpose is to assess the efficacy and safety of two doses of ACP-204 compared to placebo. The studies include a Phase 2 dose-response trial followed by two Phase 3 confirmatory trials, each analyzed separately. The research addresses the treatment of psychosis symptoms in adults aged 55 to 95 years with confirmed Alzheimers disease and psychosis. Participants receive either ACP-204 at 30 mg or 60 mg doses or a matching placebo once daily, approximately at the same time each day, with or without food. Each substudy includes a screening period lasting up to 49 days, a 6-week double-blind treatment period, and a 30-day safety follow-up for those not entering an open-label extension. Vital status follow-up is also conducted for participants who end the study early. During the study, participants undergo assessments including the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales SAPS-HD and the Clinical Global Impression-Severity in the ADP context CGI-S-ADP. Study visits involve evaluation with a designated caregiver or study partner. Safety monitoring and vital status checks continue after treatment, with the total participation duration including screening, treatment, and follow-up periods.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of LinearZ, a non-invasive focused ultrasound device, for body contouring of the lower abdomen and flanks. This study involves approximately 30 adults with localized fat in these areas and aims to determine if the treatment reduces circumference 90 days after a single session. The study is designed as a prospective, single-center, single-arm, open-label clinical trial without a control group. Each participant will receive one treatment with the LinearZ device targeting the lower abdomen and bilateral flanks. The device delivers focused ultrasound energy at specific depths within subcutaneous tissue. Treatment details such as area, cartridge type, depth, energy level, and number of shots will be recorded. Participants will be followed for about 90 days after treatment to assess safety and effectiveness. Participants will undergo screening and baseline assessments before treatment, then return for follow-ups approximately 30 and 90 days post-treatment. Researchers will measure changes in circumference at the treated areas, body contour and appearance using standardized photos and 3D imaging, and participant satisfaction. Body weight, BMI, and body composition changes will also be monitored. Safety evaluations include monitoring adverse events, pain or discomfort, and skin reactions throughout the study.
Actively Recruiting
Researchers are evaluating a new treatment combination for adults with advanced small cell lung cancer SCLC. The study compares a medicine called obrixtamig combined with standard treatment atezolizumab, carboplatin, and etoposide against the standard treatment alone. Obrixtamig is an antibody-like molecule designed to help the immune system fight cancer. The study also tests a new medical device to measure levels of a tumor marker called DLL3. Participants are randomly assigned to one of two groups. One group receives obrixtamig plus the standard treatment, while the other group receives only the standard treatment. All drugs are given through infusions into a vein. Participants in the obrixtamig group stay overnight at the study site after their first two obrixtamig treatments. The study lasts for up to three years, during which participants visit the study site regularly. Throughout the study, doctors monitor tumor size to compare results between groups. They also check participants overall health and note any side effects. Researchers measure outcomes such as overall survival, progression-free survival, symptom changes, treatment responses, and any treatment-related side effects. Participants are closely observed for up to 36 months to evaluate these effects and safety.
Actively Recruiting
This research aims to evaluate the real-life effectiveness, safety, and usage patterns of Octapharmas factor VIII FVIII concentratesNuwiq, Octanate, and Wilatein patients with severe haemophilia A who have either never been treated or have had minimal treatment. The study focuses on previously untreated patients, often young children, and minimally treated patients, gathering more data on treatment outcomes and inhibitor development to better understand optimal treatment approaches in routine clinical practice. Participants receive one of the three FVIII concentrates Nuwiq recombinant FVIII, Octanate plasma-derived FVIII, or Wilate plasma-derived FVIII combined with von Willebrand factor. The study observes how these products are used, including dosing and frequency, without altering prescribed treatments. This non-interventional study collects data during routine care to assess product utilization, safety, and effectiveness, including responses to surgical prophylaxis. During the study, researchers monitor participants for breakthrough bleeding rates and any adverse drug reactions over 100 exposure days to assess treatment effectiveness and safety. They also collect information on FVIII dosing and physicians evaluations of surgical prophylaxis effectiveness. The study involves patients of all ages and follows them through their usual clinical visits, with data gathered via observation rather than treatment changes. The study is designed to provide valuable real-world evidence on these FVIII concentrates in severe haemophilia A patients.
Actively Recruiting
Healthy Volunteer
Researchers are studying genetic and behavioral factors that might contribute to the development of certain cancers, focusing on patients with a history of cancer and their relatives. The study aims to identify families with patterns suggesting genetic susceptibility or carcinogenic exposures and to understand how heredity and biomarkers relate to clinical outcomes, including new cancers, prognosis, and quality of life. Participants may provide various biological samples such as blood, saliva, eyebrow plucks, urine, and stored tumor or healthy tissue. The study also collects information through questionnaires. These samples and data help characterize genetic predispositions and investigate biomarkers over time. Participants are involved by providing samples and family history information. Researchers will assess cancer risk and explore biomarkers over a period of up to 10 years. Deceased patients records and archived tissue samples may also be included. The study monitors outcomes related to cancer risk and biomarker findings, with long-term follow-up to understand disease patterns and prognosis.
Actively Recruiting
Researchers are evaluating how well seltorexant works and its safety when added to antidepressant treatment in adults and elderly participants with major depressive disorder who also experience insomnia symptoms. The study focuses on participants who have not adequately responded to treatment with selective serotonin reuptake inhibitors SSRIs or serotonin-norepinephrine reuptake inhibitors SNRIs. It aims to compare seltorexant with placebo as an additional therapy to improve depressive symptoms in this group. Participants will take seltorexant or a matching placebo orally once daily for 6 weeks during the double-blind phase of Part 1, while continuing their current SSRI or SNRI antidepressant. Those who complete Part 1 and meet criteria can enter Part 2, which includes open-label induction and stabilization phases where all receive seltorexant alongside their antidepressant. Participants who achieve a stable response then enter a double-blind maintenance phase in Part 2, receiving either seltorexant or placebo daily along with their antidepressant. During the study, participants will undergo assessments including depression rating scales like the Montgomery-Asberg Depression Rating Scale MADRS and patient-reported sleep disturbance measures. Researchers will monitor changes in depressive symptoms and sleep over time, track time to relapse during the maintenance phase, and evaluate safety. The total study duration may extend up to nearly three years for some participants, with follow-up after each treatment phase.
Actively Recruiting
Researchers are comparing two treatments for adults with mild-to-moderate inflammatory facial acne vulgaris in this randomized clinical trial. The study aims to evaluate and compare the effects of sequential radiofrequency RF treatment and standard topical therapy on reducing inflammatory acne lesions and facial sebum production, while also assessing safety and tolerability. Participants are randomly assigned to one of two groups. The RF group receives three sessions using the Density Noir System at 6-week intervals, with treatments targeting the entire face globally and individual inflammatory lesions. The topical group applies a fixed-combination gel containing adapalene 0.1% and benzoyl peroxide 2.5% once daily for 12 weeks. Both groups are followed for an additional 12 weeks after treatment to assess sustained effects. Throughout the 24-week study, participants undergo evaluations including lesion counts, skin redness, dermal thickness by ultrasound, quality of life measures, pain after treatments, and satisfaction with therapy. Safety is monitored by recording local skin reactions and adverse events. The primary outcome focuses on changes in inflammatory lesion count from baseline to week 12, alongside facial sebum production changes.